Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Dr. Burtness on 2 Types of Head and Neck Cancer

January 6th 2012

Dr. Barbara Burtness, from Fox Chase Cancer Center, on the 2 Types of Head and Neck Cancer

Chemoradiotherapy Shows Promise in Nonmelanoma Skin Cancer of the Head and Neck

January 4th 2012

Chemotherapy given at the same time as radiotherapy may be a feasible treatment for high-risk nonmelanoma skin cancer (NMSC) of the head and neck.

Exelixis Finds Great Promise in Cabozantinib

December 28th 2011

The investigational compound cabozantinib (formerly known as XL184) has generated much excitement in recent years for its ability to target multiple pathways involved in the development of cancer.

Hair Professionals Often Check Customers for Worrisome Skin Lesions

December 20th 2011

Some cosmetologists and barbers inspect their customers' scalps, necks, and faces for the presence of skin lesions that they think may be cancerous.

HPV Vaccine Recommendation for Boys Viewed as Necessary

December 19th 2011

As the incidence of head and neck cancers linked to the HPV continues to rise, a federal advisory panel has recommended that all 11- and 12-year-old boys be vaccinated against the virus.

Dr. Vokes on Cetuximab for Head and Neck Cancer

December 6th 2011

Dr. Everett Vokes from University of Chicago Medical Center on Cetuximab for Head and Neck Cancer

Dr. Sherman Discusses the Vandetanib Trial

December 5th 2011

Dr. Eric Sherman from Memorial Sloan-Kettering Cancer Center Discusses the Vandetanib Trial

Dr. Mehra Discusses DNA Repair Enzymes

December 5th 2011

Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes

Focusing on EGFR Resistance

December 1st 2011

Ezra E. W. Cohen, MD, has focused on the role of EGFR inhibitors in much of his research into head and neck cancers.

Dr. Cohen Discusses Head and Neck Cancer Pathways

November 29th 2011

Dr. Ezra Cohen from the University of Chicago Discusses Head and Neck Cancer Pathways

Turmeric Ingredient Inhibits Kinase in Cancer Pathway

November 21st 2011

If IKK kinase, a group of inhibitory proteins, activity is not regulated properly, tumors in the body have the ability to migrate and proliferate.

Making Oncology His Path: An Interview With Ezra E.W. Cohen, MD

November 15th 2011

Ezra E. W. Cohen, MD, is a physician and translational researcher at the University of Chicago Medical Center, that focuses on epidermal growth factor receptor (EGFR) inhibitors.

Cetuximab Approved by FDA for Patients With Late-Stage Head and Neck Cancer

November 7th 2011

Cetuximab (Erbitux) was approved by the FDA for treating patients with late-stage head and neck cancer in combination with chemotherapy.

October 2011: Trials in Progress

October 21st 2011

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Meeting.

Dr. Burtness on the Head and Neck Symposium Design

September 28th 2011

Dr. Barbara Burtness from Fox Chase Cancer Center on the Head and Neck Symposium Design

Dr. Burtness on the Head and Neck Cancer Symposium

September 27th 2011

Dr. Barbara Burtness from Fox Chase Cancer Center Discusses the Upcoming Head and Neck Cancer Symposium

Panitumumab Extends Progression-Free Survival in HPV-Negative Subset of Advanced Head and Neck Cancer

September 25th 2011

Panitumumab + chemo improves OS and PFS in patients with metastatic carcinoma of the head and neck that were negative for HPV.

Conference Corner: 2 Upcoming Physicians' Education Resource Conferences

August 31st 2011

The 2 upcoming conferences include the 7th Annual Multidisciplinary Symposium on Head and Neck Cancer and the School of Breast Oncology.

ASCO Highlights: Trials in Progress

August 23rd 2011

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Study Shows No Survival Benefit of Cetuximab Over Cisplatin-Based Chemoradiation in Head and Neck Cancers

August 4th 2011

Patients with locally advanced head and neck cancer gained no survival benefit with the addition of cetuximab to chemoradiation.